BioWorld

Jan. 28, 2004

View Archived Issues

Dendreon Pulls In $130.7M In Public Offering For Provenge

In the second biotech public offering of the year, Dendreon Corp. raised $130.7 million, money that will be used to fund clinical trials and develop a commercial infrastructure for Provenge. (BioWorld Today) Read More

SuperGen Completes Orathecin Pancreatic Cancer Rolling NDA

Read More

Sirna Agrees To RNAi Cancer Drug Collaboration With Lilly

Read More

Cellegesic Hits Primary Endpoint; Cellegy Expects Summer Filing

Read More

Other News To Note

Read More

Appointments And Advancements

Read More